Table 4 Multiple Linear Regression analysis results for influential factors of the adverse effect of Apatinib treatment.

From: Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial

 

MLR parameters

Sex

Age

Medical History

Radiotherapy History

Prior Treatment

Adverse Effects

Beta

−0.23

0.02

−0.61

−0.45

0.00

Low Limit

−0.64

0.01

−1.02

−0.85

0.00

Up Limit

0.17

0.04

−0.20

−0.05

0.00

p-value

0.90

<0.01

1.00

1.00

0.50

Treatment efficacy

Beta

−0.03

0.011

−0.25

0.001

0.00

Low Limit

−0.58

−0.01

−0.80

−0.54

0.00

Up Limit

0.52

0.04

0.31

0.55

0.00

p-value

0.54

0.13

0.84

0.49

0.5